Praxis Precision Medicines making progress with potential assets, strong financial support.
From GlobeNewswire: 2025-01-12 21:00:00
Praxis Precision Medicines is making significant progress with three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025, with the anticipation of four commercial assets by 2028. The company’s Essential3 program for ulixacaltamide in essential tremor is on track for an interim analysis in Q1 2025, while the enrollment in the EMBOLD study of relutrigine cohort 2 is progressing for an NDA filing in 2026. Additionally, the Vormatrigine ENERGY program is advancing with read-outs expected in 2025, and UCB has exercised its option to license a small molecule candidate for global development and commercialization. Praxis has strong financial support with cash and investments of approximately $470 million at the end of 2024, providing runway into 2028.
Praxis Precision Medicines is focused on advancing its portfolio with multiple programs targeting CNS disorders, including essential tremor, common epilepsies, and developmental and epileptic encephalopathies. Their innovative approaches and promising results are setting the stage for potential product launches in the coming years. With a robust pipeline and strategic collaborations, Praxis is well-positioned to make a significant impact in the field of genetic insights and therapeutic development for neurological disorders.
Read more at GlobeNewswire: Praxis Precision Medicines Highlights 2025 Corporate